William Blair initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and fair value estimated of $9. The stock closed at $3.14 on Jan. 17. Selecta is focused on its ImmTOR platform, which...
H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $12 from $7, saying the expected data flow, and available activity and safety profile bode well for the company’s XMT-1536 drug candidate...
Mackie Research Capital put Acasti Pharma (NASDAQ, TSXV:ACST) “under review” and removed its price target after the company’s pivotal TRILOGY-1 trial missed its primary endpoint because of an unexplained high placebo...
Roth Capital Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $35 price target. The stock closed at $7.63 on Jan. 9. Millendo is a clinical-stage company focusing on the...
SVC Leerink initiated coverage of Organogenesis (NASDAQ:ORGO) with an “outperform” rating and $9 price target. The stock closed at $4.84 on Jan. 9. Organogenesis is a regenerative medicine company with a portfolio of...
Canaccord Genuity raised its price target for Profound Medical (NASDAQ:PROF; TSX:PRN) to $20 from $14 after the company announced preliminary Q4-2019 results. Shares of Profound were quoted at $14.72, up $1.73, or 13%...
Maxim Group raised its price target for Cassava Sciences (NASDAQ:SAVA) to $12 from $3, citing the recent rise in the company’s share price. The stock closed at $7.93 on Jan. 9. “Cassava’s shares have risen significantly...
William Blair launched coverage of iRhythm Technologies (NASDAQ:IRTC) with an “outperform” rating, calling the company’s digital health platform “market disrupting.” The stock closed at $71.76, up $1.12, on Jan. 9...
Echelon Wealth Partners reiterated top pick status to Acasti Pharma (TSXV:ACST) and Antibe Therapeutics (TSXV:ATE). Acasti is developing an omega-3-based therapeutic for the treatment of hyperglyceridemia. Analyst Doug...
William Blair initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with an “outperform” rating and estimated fair value of $27. The stock closed at $13.49 on Jan. 7. Xenon is focused on the development of selective...